In the claims:

Please amend claims 1-9, 11, 12, 14, 15, 17-19, 23, 25, 27, and 28-30.

Please cancel claims 10, 13, 16, 20-22, 24, and 26.

Please add new claims 31-43.

1. **(Currently amended)** A pharmaceutical composition comprising ~~a combination of~~

i) at least one peptide which is shorter than the N2 sequence of the RasGAP protein and comprises ~~comprising~~ the ~~general~~ amino acid sequence WXWVTXXRTX, or variants thereof, wherein X represents an amino acid,

ii) and a genotoxin,

~~characterized in that~~ wherein said at least one peptide enhances the ability of said genotoxin to kill selectively cancer cells.

2. **(Currently amended)** The pharmaceutical composition of claim 1, wherein ~~characterized in that~~ said at least one peptide ~~shorter than the N2 sequence of the RasGAP protein~~ comprises at least one amino acid sequence encoded by the DNA sequences selected from the group consisting of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, and ~~or~~ SEQ ID No.4.

3. **(Currently amended)** The pharmaceutical composition of claim 1, wherein ~~claims 1-2, characterized in that~~ said at least one peptide ~~shorter than the N2 sequence of the RasGAP protein~~ comprises the amino acid sequence WMWVTNLRTD.

4. **(Currently amended)** The pharmaceutical composition of claim 1, wherein ~~claims 1-3, characterized in that~~ said at least one peptide ~~shorter than the N2 sequence of the RasGAP protein~~ is in D-form and/or in a retro-inverso isomer form.

5. **(Currently amended)** The pharmaceutical composition of claim 1, wherein ~~claims 1 to 4, characterized in that~~ said at least one peptide ~~shorter than the N2 sequence of the RasGAP protein~~ is conjugated to an agent which increases the cell accumulation of said at least one peptide.

6. **(Currently amended)** The pharmaceutical composition of claim 5, wherein ~~characterized in that~~ the agent is a cell membrane permeable carrier.

7. **(Currently amended)** The pharmaceutical composition of claim 6, wherein ~~characterized in that~~ the cell membrane permeable carrier is a peptide.

8. **(Currently amended)** The pharmaceutical composition of claim 7, wherein ~~characterized in that~~ the cell membrane permeable carrier peptide is in D-form and/or in a retro-inverso isomer form.

9. **(Currently amended)** The pharmaceutical composition of claim 7 ~~claims 7-8~~, wherein ~~characterized in that~~ the cell membrane permeable carrier peptide is an arginine rich peptide which is selected from the group consisting of ~~comprising the~~ an HIV-TAT $_{48-57}$ peptide, ~~the~~ an FHV-coat $_{35-49}$ peptide, ~~the~~ an HTLV-II Rex $_{4-16}$ peptide, and ~~the~~ a BMV gag $_{7-25}$ peptide.

10. **(Canceled)**

11. **(Currently amended)** The pharmaceutical composition of claim 1, wherein ~~claims 1 to 10, characterized in that~~ the genotoxin is selected from the group consisting of ~~comprising~~ an alkylating agents~~,~~ an antimetabolites~~,~~ a DNA cutters~~,~~ a DNA binders~~,~~ a topoisomerase poisons~~,~~ and a spindle poisons~~.~~

12. **(Currently amended)** The pharmaceutical composition of claim 11, wherein ~~characterized in that~~ said alkylating agents is ~~are~~ selected from the group consisting of ~~comprising~~ lomustine, carmustine, streptozocin, mechlorethamine, melphalan, uracil nitrogen mustard, chlorambucil, cyclosphamide, iphosphamide, cisplatin, carboplatin, mitomycin, thiotepa, dacarbazin, procarbazine, hexamethyl melamine, triethylene melamine, busulfan, pipobroman, mitotane, and other platinum ~~platine~~ derivatives.

13. **(Canceled)**

14. **(Currently amended)** The pharmaceutical composition of claim 11, wherein ~~characterized in that~~ the DNA cutter is bleomycin.

15. **(Currently amended)** The pharmaceutical composition of claim 11, wherein ~~characterized in that~~ the toposiomerase poisons ~~is are~~ selected from the group consisting of ~~comprising~~ topotecan, irinotecan, camptothecin sodium salt, daorubicin, doxorubicin, idarubicin, mitoxantrone, teniposide, adriamycin, and etoposide.

16. **(Canceled)**

17. **(Currently amended)** The pharmaceutical composition of claim 11, wherein ~~characterized in that~~ the DNA binders ~~is are selected from the group comprising~~ dactinomycin or ~~and~~ mithramycin.

18. **(Currently amended)** The pharmaceutical composition of claim 11, wherein ~~characterized in that~~ the spindle poisons ~~is are~~ selected from the group consisting of ~~comprising~~ vinblastin, vincristin, navelbin, paclitaxel, and docetaxel.

19. **(Currently amended)** The pharmaceutical composition of claim 11, wherein ~~characterized in that~~ the antimetabolites ~~is are~~ selected from the group consisting of ~~comprising~~ methotrexate, trimetrexate, pentostatin, cytarabin, ara-CMP, fludarabine phosphate, hydroxyurea, fluorouracyl, floxuridine, chlorodeoxyadenosine, gemcitabine, thioguanine, and 6-mercaptopurine.

20. **(Canceled)**

21. **(Canceled)**

22. **(Canceled)**

23. **(Currently amended)** The method ~~use~~ according to claim 40 ~~22~~, wherein ~~characterized in that~~ the cancer is selected from the group consisting of carcinoma, lymphoma, blastoma, sarcoma, liposarcoma, neuroendocrine tumor, mesothelioma, schwanoma, meningioma, adenocarcinoma, melanoma, leukemia, lymphoid malignancy, squamous cell cancer, epithelial squamous cell cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophageal cancer, a tumor of the biliary tract, and head and neck cancer.

24. **(Canceled)**

25. **(Currently amended)** A method of treating or preventing cancer selected from the group consisting of carcinoma, lymphoma, blastoma, sarcoma, liposarcoma, neuroendocrine tumor, mesothelioma, schwanoma, meningioma, adenocarcinoma, melanoma, leukemia, lymphoid malignancy, squamous cell cancer, epithelial squamous cell cancer, lung cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, testicular cancer, esophageal cancer, a tumor of the biliary tract, and head and neck cancer, comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 1 ~~claims 1 to 20~~ to a subject in need thereof, such that said cancer is treated or prevented.

26. **(Canceled)**

27. **(Currently amended)** A method for enhancing apoptosis selectively in a cancer cell, comprising contacting a cancer cell with the pharmaceutical composition of claim 1.~~claims 1 to 20.~~

28. **(Currently amended)** A method for selectively killing cancer cells comprising contacting a cancer cell with the pharmaceutical composition of claim 1.~~claims 1 to 20.~~

29. **(Currently amended)** A kit for treating or preventing cancer in a subject comprising the pharmaceutical composition of claim 1, ~~any of claims 1 to 20 optionally with reagents and/or~~ and instructions for use.

30. **(Currently amended)** The kit of claim 29, further comprising a separate pharmaceutical dosage form including an additional anti-cancer agent selected from the group consisting of drugs, anti-epidermal growth factor receptors antibodies, radioimmunotherapeutic agents, and combinations thereof.

31. **(New)** A kit for treating or preventing cancer in a subject comprising

i) at least one peptide which is shorter than the N2 sequence of the RasGAP protein and comprises the amino acid sequence WXWVTXXRTX, or variants thereof, wherein X represents an amino acid; and

ii) instructions for use of said at least peptide.

32. **(New)** The kit of claim 31, further comprising a genotoxin.

33. **(New)** A method for enhancing apoptosis in a cancer cell, comprising contacting the cancer cell with

i) at least one peptide which is shorter than the N2 sequence of the RasGAP protein and comprises the amino acid sequence WXWVTXXRTX, or variants thereof, wherein X represents an amino acid, and

ii) a genotoxin,

wherein said at last one peptide enhances the ability of said genotoxin to selectively kill said cancer cell.

34. **(New)** The method of claim 33, wherein said at least one peptide comprises the SH3 domain of the N2 sequence, or a part thereof, or comprises at least one amino acid sequence encoded by a DNA sequence selected from the group consisting of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, and SEQ ID No.4.

35. **(New)** The method of claim 33, wherein the genotoxin is selected from the group consisting of an alkylating agent, an antimetabolite, a DNA cutter, a DNA binder, a topoisomerase poison, and a spindle poison.

36. **(New)** The method of claim 33, wherein the genotoxin is selected from the group consisting of cisplatin, mitoxantrone and adriamycin.

37. **(New)** A method for enhancing the sensitivity of a cancer cell to a genotoxin comprising contacting the cancer cell with at least one peptide which is shorter than the N2 sequence of the RasGAP protein and comprises the amino acid sequence WXWVTXXRTX, or variants thereof, wherein X represents an amino acid.

38. **(New)** The method of claim 37, wherein said at least one peptide comprises the SH3 domain of the N2 sequence, or a part thereof, or comprises at least one amino acid sequence encoded by a DNA sequence selected from the group consisting of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, and SEQ ID No.4.

39. **(New)** The pharmaceutical composition of claim 1, wherein said at least one peptide comprises the SH3 domain of the N2 sequence, or a part thereof.

40. **(New)** A method of treating or preventing cancer in a subject comprising administering to said subject

i) at least one peptide which is shorter than the N2 sequence of the RasGAP protein and comprises the amino acid sequence WXWVTXXRTX, or variants thereof, wherein X represents an amino acid, and

ii) a genotoxin,

wherein said at least one peptide enhances the ability of said genotoxin to kill selectively cancer cells, such that said cancer is treated or prevented.

41. **(New)** The method of claim 40, wherein said at least one peptide comprises the SH3 domain of the N2 sequence, or a part thereof, or comprises at least one amino acid sequence encoded by a DNA sequence selected from the group consisting of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, and SEQ ID No.4.

42. **(New)** The method of claim 40, wherein the genotoxin is selected from the group consisting of an alkylating agent, an antimetabolite, a DNA cutter, a DNA binder, a topoisomerase poison, and a spindle poison.

43. **(New)** The pharmaceutical composition of claim 40, wherein the genotoxin is selected from the group consisting of cisplatin, mitoxantrone and adriamycin.